Our research strongly supports our idea that HERV-K (HML-2) activation in COVID-19 patients might promote cGAS-STING pathway activation and regulate the SUMO pathway and β-defensin production, thus inducing IFN-I production. This evidence concerns the gene CLEC10A and COVID-19.